Rigel Pharmaceuticals (RIGL) said Thursday that it has settled with Annora Pharma, Hetero Labs, and Hetero USA, resolving patent litigation related to its product Tavalisse.
Rigel said the litigation arose after Annora submitted an abbreviated new drug application to the US Food and Drug Administration seeking approval for a generic version of Tavalisse.
Rigel said the settlement allows Annora to be licensed to sell its generic version starting in Q2 2032 or earlier under certain conditions.
The settlement also ends all ongoing litigation between Rigel and Annora over Tavalisse patents in New Jersey, Rigel said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。